BRNS
Barinthus Biotherapeutics plcHealthcare · $30M market cap
Verdict
We can't put a fair value on BRNS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow BRNS
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 9, 2026: no open-market purchases and 49 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
DAWES KAREN A
director · 2026-09-09
D-Return
$20K
DAWES KAREN A
director · 2026-09-09
D-Return
$46K
DAWES KAREN A
director · 2026-09-09
D-Return
$44K
DAWES KAREN A
director · 2026-09-09
D-Return
$79K
DAWES KAREN A
director · 2026-09-09
D-Return
$584K
Show all 49 other filingsShow fewer
DAWES KAREN A
director · 2026-09-09
D-Return
$0
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$600K
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$1.6M
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$1.1M
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$4.0M
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$3.0M
Enright William
Chief Executive Officer · 2026-09-09
D-Return
$51
Hammacher Alex
director · 2026-09-09
D-Return
$20K
Hammacher Alex
director · 2026-09-09
D-Return
$46K
Hammacher Alex
director · 2026-09-09
D-Return
$44K
Hammacher Alex
director · 2026-09-09
D-Return
$79K
Hammacher Alex
director · 2026-09-09
D-Return
$584K
Hammacher Alex
director · 2026-09-09
D-Return
$0
Hooftman Leon
Chief Medical Officer · 2026-09-09
D-Return
$140K
Hooftman Leon
Chief Medical Officer · 2026-09-09
D-Return
$390K
Hooftman Leon
Chief Medical Officer · 2026-09-09
D-Return
$36
Hooftman Leon
Chief Medical Officer · 2026-09-09
Award
$36
Morgon Pierre A.
director · 2026-09-09
D-Return
$20K
Morgon Pierre A.
director · 2026-09-09
D-Return
$46K
Morgon Pierre A.
director · 2026-09-09
D-Return
$44K
Morgon Pierre A.
director · 2026-09-09
D-Return
$79K
Morgon Pierre A.
director · 2026-09-09
D-Return
$584K
Morgon Pierre A.
director · 2026-09-09
D-Return
$2
Morgon Pierre A.
director · 2026-09-09
D-Return
$1
Phillips Anne M.
director · 2026-09-09
D-Return
$20K
Phillips Anne M.
director · 2026-09-09
D-Return
$46K
Phillips Anne M.
director · 2026-09-09
D-Return
$44K
Phillips Anne M.
director · 2026-09-09
D-Return
$79K
Phillips Anne M.
director · 2026-09-09
D-Return
$584K
Phillips Anne M.
director · 2026-09-09
D-Return
$0
Scheeren Joseph
director · 2026-09-09
D-Return
$20K
Scheeren Joseph
director · 2026-09-09
D-Return
$46K
Scheeren Joseph
director · 2026-09-09
D-Return
$44K
Scheeren Joseph
director · 2026-09-09
D-Return
$79K
Scheeren Joseph
director · 2026-09-09
D-Return
$584K
Scheeren Joseph
director · 2026-09-09
D-Return
$2
Wright Robin
director · 2026-09-09
D-Return
$584K
Wright Robin
director · 2026-09-09
D-Return
$2
Wright Robin
director · 2026-09-09
D-Return
$5
Wright Robin
director · 2026-09-09
D-Return
$20K
Wright Robin
director · 2026-09-09
D-Return
$46K
Wright Robin
director · 2026-09-09
D-Return
$44K
Wright Robin
director · 2026-09-09
D-Return
$79K
Oxford Science Enterprises plc
Owns 10%+ · 2026-09-09
U-Tender
$977K
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Sep 8, 2026. How the Payback Price works